News

Press Releases

Jun 4

Inflection Biosciences Announces Pre-Clinical Data for IBL-202 in PTCL Presented at the Inaugural West German Lymphoma Symposium

Dublin, Ireland, June 4 2024 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of...

Aug 21, 2023

Inflection Biosciences Announces Licensing of PIM kinase Inhibitors to Mysthera Therapeutics

Dublin, Ireland, August 21 2023 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of...

Dec 5, 2022

Inflection Biosciences Announces Pre-clinical data for IBL-101 to be Presented at BSI Congress 2022

Dublin, Ireland, December 5, 2022 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...

May 30, 2022

Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence

ESCHBORN, Germany, May 30, 2022 Innoplexus, a global leader in AI-based drug discovery and development, and Inflection Biosciences Ltd.,...

May 27, 2022

Inflection Biosciences Announces Expansion of Research into Autoimmune and Inflammatory Disease

Expands Advisory Panel with Immunology and Rheumatology Expertise Dublin, Ireland, May 27, 2022 Inflection Biosciences Ltd, a company...

Nov 11, 2021

Inflection Biosciences Announces Publication on Discovery of AUM302 in ACS Medicinal Chemistry

Dublin, Ireland, November 10, 2021 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...